BioAge Labs (BIOA) shares slumped 70% pre-bell Monday after the company said late Friday it is terminating a phase 2 trial of its obesity drug candidate following observations of liver transaminitis.
Universe Pharmaceuticals (UPC) shares fell 54% after the company unveiled a $15 million registered direct offering of ordinary shares and warrants.
Radiopharm Theranostics (RADX) shares dropped 25% after Friday's 7% increase.
Palmer Square Capital (PSBD) shares retreated 18% following a 1.3% gain in the previous session.
Forrester Research (FORR) shares were down 17% following a muted session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。